What Can Patients With HFpEF Gain From Iron Supplementation?
A recent study investigated the effects of intravenous ferric carboxymaltose (FCM) on patients with heart failure with preserved ejection fraction (HFpEF) and iron deficiency. While FCM normalized blood iron levels in many patients, it did not lead to improvements in exercise hemodynamics or myocardial energy metabolism. The study suggests potential benefits in right ventricular function and exercise tolerance, despite its limitations.
- ▪The study included 45 patients with HFpEF and iron deficiency, with 42 completing the trial.
- ▪FCM treatment resolved iron deficiency in 15 of 20 recipients and significantly increased ferritin and transferrin saturation levels.
- ▪Despite improvements in right ventricular ejection fraction and walk distance, FCM did not change exercise hemodynamics or cardiac energy measures.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:In patients with heart failure with preserved ejection fraction (HFpEF) and iron deficiency without anaemia, intravenous ferric carboxymaltose (FCM) normalised blood iron levels but did not improve exercise haemodynamics or myocardial energy metabolism.METHODOLOGY:Researchers conducted a phase 2, double-blind, randomized clinical trial (IRON-HFpEF) at two Dutch centres to assess whether intravenous FCM could improve cardiovascular function and exercise tolerance in patients with HFpEF and iron deficiency without anaemia.They included 45 patients (mean age, 69 years; 78% women) between August 2020 and February 2023, with 42 patients completing the trial.Patients were randomly assigned to receive FCM dosed according to body weight and haemoglobin levels (median dose, 1000 mg) or…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
